Miglustat Accord Healthcare (Miglustat)

Miglustat is employed in substrate reduction therapy targeting lysosomal storage disorders.

• Niemann-Pick disease type C: improves neurological function and slows disease progression.
• Gaucher disease type 1 (adjunct therapy): reduces glycosphingolipid accumulation when enzyme replacement is insufficient.

• Miglustat inhibits the enzyme glucosylceramide synthase, the first step in the biosynthesis of glycosphingolipids. By blocking this pathway, the drug reduces the production of glucosylceramide and downstream complex sphingolipids that accumulate in lysosomal storage diseases. The resulting decrease in substrate load alleviates cellular dysfunction and mitigates disease manifestations. It acts competitively at the enzyme’s active site, producing a dose‑dependent reduction of glycosphingolipid synthesis while sparing other lipid metabolic routes.

Miglustat may cause a range of adverse reactions, most of which involve the gastrointestinal system.

Common Side Effects

• Diarrhea: frequent loose stools often occurring early in therapy.
• Nausea: feeling of sickness that may be mild to moderate.
• Abdominal pain: cramping or discomfort in the stomach area.
• Weight loss: gradual reduction in body weight with prolonged use.
• Flatulence: increased intestinal gas production.

Serious or Rare Side Effects

• Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
• Severe allergic reactions: rash, itching, swelling, or anaphylaxis.
• Liver enzyme elevations: increased ALT or AST indicating hepatic stress.
• Depression or mood changes: new onset or worsening of depressive symptoms.

When prescribing Miglustat, clinicians should observe several safety considerations to minimize risks.

• Monitor gastrointestinal tolerance: assess frequency and severity of diarrhea, nausea, and abdominal pain.
• Evaluate body weight regularly: watch for unintended weight loss and provide nutritional support if needed.
• Check liver function tests: baseline and periodic monitoring of ALT/AST levels.
• Observe for signs of pancreatitis: severe abdominal pain, vomiting, or elevated pancreatic enzymes.
• Assess for hypersensitivity: discontinue if rash, swelling, or anaphylactic signs develop.
• Store at below 25°C: keep tablets in the original packaging, protect from moisture and direct light.

Miglustat can interact with other medicines, affecting absorption or increasing toxicity.

Major Interactions (Avoid)

• Concomitant use with strong intestinal disaccharidase inhibitors (e.g., acarbose): may exacerbate gastrointestinal side effects.
• Co‑administration with oral antidiabetic agents (e.g., insulin, sulfonylureas): increased risk of hypoglycemia due to altered carbohydrate absorption.

Moderate Interactions (Monitor Closely)

• Warfarin: monitor INR as miglustat may affect anticoagulant stability.
• Oral contraceptives: reduced efficacy possible; advise additional contraceptive measures.
• Other substrate reduction therapies: additive effect on glycosphingolipid inhibition may increase toxicity.
• Antiepileptic drugs: monitor seizure control as miglustat may influence drug levels.